In Vivo mRNA CAR-T

In vivo mRNA CAR-T is the 2025 combination-innovation direction discussed in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The episode describes using mRNA-LNP delivery inside the body so T cells are modified without extracting, engineering, and reinfusing them through a conventional [[ExVivoCARTManufacturing|ex vivo]] process.

The source’s key caveat is duration. mRNA expression is shorter-lived, so the resulting CAR-T-like effect may not persist long enough for many oncology uses. The episode therefore treats autoimmune disease as a plausible early fit, because some contexts may need a temporary clearance of selected cells rather than durable anti-tumor persistence.

Key Claims

• In vivo mRNA CAR-T is a specific route within In Vivo CAR-T, not a synonym for all in vivo CAR-T.
• It tries to lower manufacturing burden by moving cell modification into the patient.
• Short mRNA expression creates persistence limits.
• The source sees autoimmune disease as a more plausible near-term fit than durable solid-tumor oncology.

Connections

• In Vivo CAR-T, CAR-T Cell Therapy, and Ex Vivo CAR-T Manufacturing - parent cell-therapy routes.
• Allogeneic CAR-T - separate off-the-shelf route also discussed as limited by efficacy and persistence.
• T-Cell Engagers - adjacent lower-cost immune-cell redirection approach.
• Solid Tumor CAR-T Constraints and Cytokine Release Syndrome - efficacy and safety context.